We therefore nominate the CoA biosynthetic pathway as a metabolic vulnerability in PDGF/VEGF- and MYC-driven tumors, proposing that inhibition of CoA biosynthesis, alone or in combination with anti-angiogenic regimens, may help restrict metabolic adaptation and impede tumor progression. This evidence concerns the gene MYC and neoplasm.